These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 29178361)
1. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Jabbour E; Düll J; Yilmaz M; Khoury JD; Ravandi F; Jain N; Einsele H; Garcia-Manero G; Konopleva M; Short NJ; Thompson PA; Wierda W; Daver N; Cortes J; O'brien S; Kantarjian H; Topp MS Am J Hematol; 2018 Mar; 93(3):371-374. PubMed ID: 29178361 [TBL] [Abstract][Full Text] [Related]
2. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment. Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435 [TBL] [Abstract][Full Text] [Related]
3. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611 [TBL] [Abstract][Full Text] [Related]
4. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of blinatumomab: a real world data. Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826 [TBL] [Abstract][Full Text] [Related]
6. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056 [TBL] [Abstract][Full Text] [Related]
7. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Aldoss I; Song J; Stiller T; Nguyen T; Palmer J; O'Donnell M; Stein AS; Marcucci G; Forman S; Pullarkat V Am J Hematol; 2017 Sep; 92(9):858-865. PubMed ID: 28494518 [TBL] [Abstract][Full Text] [Related]
8. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia. Contreras CF; Higham CS; Behnert A; Kim K; Stieglitz E; Tasian SK Pediatr Blood Cancer; 2021 Jan; 68(1):e28718. PubMed ID: 33098744 [TBL] [Abstract][Full Text] [Related]
9. Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy. Qi Y; Liu H; Li X; Shi Y; Mu J; Li J; Wang Y; Deng Q Ann Med; 2023 Dec; 55(1):2230888. PubMed ID: 37417690 [TBL] [Abstract][Full Text] [Related]
10. Cytogenetic guided therapy using blinatumomab and inotuzumab ozogamicin in a patient with relapse/refractory acute lymphoblastic leukemia. Ohana Z; Serraes S; Elder C; Katusa N J Oncol Pharm Pract; 2022 Jul; 28(5):1269-1275. PubMed ID: 35043731 [TBL] [Abstract][Full Text] [Related]
11. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Zhao Y; Aldoss I; Qu C; Crawford JC; Gu Z; Allen EK; Zamora AE; Alexander TB; Wang J; Goto H; Imamura T; Akahane K; Marcucci G; Stein AS; Bhatia R; Thomas PG; Forman SJ; Mullighan CG; Roberts KG Blood; 2021 Jan; 137(4):471-484. PubMed ID: 32881995 [TBL] [Abstract][Full Text] [Related]
12. Antibody based therapy in relapsed acute lymphoblastic leukemia. Jammal N; Chew S; Jabbour E; Kantarjian H Best Pract Res Clin Haematol; 2020 Dec; 33(4):101225. PubMed ID: 33279181 [TBL] [Abstract][Full Text] [Related]
13. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090 [TBL] [Abstract][Full Text] [Related]
14. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis. Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia. Ribera JM Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835 [TBL] [Abstract][Full Text] [Related]
16. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study. Lee SH; Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Lee JW; Lee S Int J Hematol; 2022 Jan; 115(1):135-139. PubMed ID: 34617186 [TBL] [Abstract][Full Text] [Related]
17. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091 [TBL] [Abstract][Full Text] [Related]
18. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Jabbour EJ; Gökbuget N; Kantarjian HM; Thomas X; Larson RA; Yoon SS; Ghobadi A; Topp MS; Tran Q; Franklin JL; Forman SJ; Stein AS Cancer; 2019 Dec; 125(23):4181-4192. PubMed ID: 31433496 [TBL] [Abstract][Full Text] [Related]
19. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339 [TBL] [Abstract][Full Text] [Related]